Evotec SE

NasdaqGS:EVO Aktierapport

Börsvärde: US$953.9m

Evotec Tidigare resultatutveckling

Tidigare kriterier kontrolleras 0/6

Evotec s intäkter har minskat med en genomsnittlig årlig takt på -47.9%, medan Life Sciences -branschen såg intäkter på sjunkande 3.8% årligen. Intäkterna har varit växande med en genomsnittlig takt på 6.4% per år.

Viktig information

-47.94%

Tillväxttakt i vinsten

-48.58%

Tillväxttakt för EPS

Life Sciences Tillväxt i branschen21.51%
Intäkternas tillväxttakt6.36%
Avkastning på eget kapital-27.71%
Nettomarginal-26.02%
Nästa resultatuppdatering13 Aug 2026

Senaste uppdateringar av tidigare prestationer

Recent updates

Seeking Alpha • Jul 23

Evotec: Recovery Seems To Be Beginning

Summary Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis. Risks are significant, but Evotec's growth prospects and current valuation justify maintaining my position for potential outsized returns over several years. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Evotec: Some Recovery Has Come, But Much More Is Expected

Summary Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside. I maintain a price target of €20/share ($11/share for the Nasdaq ticker), viewing Evotec as a speculative investment with a risk/reward-adjusted upside. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Evotec: Weak Performance, But Long-Term Potential Is There

Summary Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition. Evotec is a speculative "buy" with high potential but significant risks; I recommend holding and watching for now, not buying more. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Evotec: Still A Speculative Buy After A Significant Decline

Summary Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts. The change in reporting structure and the stepping down of the CEO have also contributed to the decline in share price. I am still saying "Spec BUY", but with care. Read the full article on Seeking Alpha
Seeking Alpha • Oct 17

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO) said the two companies expanded their translational BRIDGE partnership LAB150, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion goes along with a combined investment of $14M to expedite LAB150 programs for forming new life science companies, Evotec said in a statement on Monday. TIAP and Evotec created LAB150 in 2017 to accelerate Toronto's academic research into market-ready products. Amgen will provide financial support for chosen LAB150 projects and mentorship from its drug discovery and development teams. In addition, Amgen Ventures will evaluate LAB150-derived companies for venture investment, Evotec noted. "Together with Evotec, we look forward to collaborating with Amgen to bring enhanced expertise and capital to LAB150 to enable life science company creation,” said TIAP President and CEO Parimal Nathwani.
Seeking Alpha • Sep 20

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-based unit Just - Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of phase 1 first-in-human (FIH) trials, the company said in a Sept. 20 press release. To enable rapid development, Just - Evotec will use its data-driven, automated biologics technology platform J.DESIGN and continuous manufacturing at its J.POD Redmond, Washington (U.S.) facility. Evotec will also provide pre-clinical and clinical capabilities for mAb prophylactic approvals. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). EVO -5.24% to $9.41 premarket Sept. 20
Seeking Alpha • Aug 25

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Evotec (NASDAQ:EVO) (OTCPK:EVOTF) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec said in an Aug. 25 press release that the contract was signed on Aug. 24 at a purchase price of €1. Evotec added it intends to invest in the coming years to establish the facility as a European center of excellence for rare disease drug substance manufacturing. Evotec said Central Glass will now operate as Evotec Drug Substance (Germany) GmbH (Evotec DS). Central Glass is located on a pharmaceutical manufacturing campus in Halle/Westphalia and has a team of ~60 chemical manufacturing experts. The transaction is expected to close on Nov. 1, subject to conditions. Evotec noted that earnings accretion is expected to be achieved by 2023/24. EVO +1.11% to $11.87 premarket Aug. 25
Seeking Alpha • Aug 10

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Evotec (NASDAQ:EVO) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences (NASDAQ:ALPN) to develop a commercial process for ALPN-303. Evotec said ALPN-303 is being developed to treat systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of the companies first-in-human program initiated in 2020 in which Just - Evotec delivered drug substance materials for Alpine's ongoing phase 1 study and anticipated phase 2 studies of ALPN-303. Under the expanded contract, Just - Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN‑303. Commercial process development activities will be undertaken at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington. EVO -10.15% to $12.66 premarket Aug. 10
Seeking Alpha • Jul 06

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Boehringer Ingelheim, Evotec (NASDAQ:EVO) (OTCPK:EVOTF) and bioMérieux formed a joint venture called Aurobac Therapeutics SAS to develop antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Aurobac, which will develop a new precision medicine approach from diagnosis to cure, was funded with €40M in total with Boehringer Ingelheim investing €30M and Evotec and bioMérieux funding €5M each, according to the companies' July 6 press release. "Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results," said bioMérieux Chairman and CEO Alexandre Mérieux. Boehringer's participation in Aurobac is part of a wider pandemic preparedness initiative, which includes a €50M investment in AMR. Boehringer Ingelheim Venture Fund has committed to invest up to €12M in AMR infection companies.

Fördelning av intäkter och kostnader

Hur Evotec tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

NasdaqGS:EVO Intäkter, kostnader och resultat (EUR Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
31 Mar 26745-19417033
31 Dec 25788-10417638
30 Sep 25756-15918342
30 Jun 25777-15618745
31 Mar 25788-20719250
31 Dec 24797-19618851
30 Sep 24777-17118061
30 Jun 24788-17117367
31 Mar 24777-9117366
31 Dec 23781-8417069
30 Sep 23821-9517470
30 Jun 23798-10317771
31 Mar 23800-11616777
31 Dec 22751-17615677
30 Sep 22698-18014474
30 Jun 22684212674
31 Mar 226509011672
31 Dec 2161821610572
30 Sep 215712479071
30 Jun 215411128770
31 Mar 21515428167
31 Dec 2050167764
30 Sep 20485147863
30 Jun 20470357259
31 Mar 20462426859
31 Dec 19446386658
30 Sep 19419616256
30 Jun 19404776055
31 Mar 19398945845
31 Dec 18375845736
30 Sep 18370635426
30 Jun 18338315419
31 Mar 18294204818
31 Dec 17264234218
30 Sep 17215283918
30 Jun 17193353118
31 Mar 17178362918
31 Dec 16165282718
30 Sep 16160182418
30 Jun 1614862519
31 Mar 16144172519
31 Dec 15128172518
30 Sep 15119122417
30 Jun 15104112115

Kvalitetsintäkter: EVO är för närvarande olönsam.

Växande vinstmarginal: EVO är för närvarande olönsam.

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: EVO är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 47.9% per år.

Accelererande tillväxt: Det går inte att jämföra EVO s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt

Resultat vs industri: EVO är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Life Sciences branschen ( 3.8% ).

Avkastning på eget kapital

Hög ROE: EVO har en negativ avkastning på eget kapital ( -27.71% ), eftersom det för närvarande är olönsamt.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/17 14:43
Aktiekurs vid dagens slut2026/05/15 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Evotec SE bevakas av 23 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc